Abstract:It is increasingly understood that cancers can be recognized by the immune system and inflammation relates to response. Combining stereotactic radiotherapy (SBRT), to increase release of cancer cell antigens, with an anti-CTLA-4 and PD-L1 inhibitor may lead to increased response rates. No solid biomarker in predicting treatment response is available. We set out to study feasibility of combined durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) with SBRT on the primary tumor. The extend of tumor-infiltrating cells has shown to correlate to improved prognosis using checkpoint inhibitor (CPI) treatment of various cancers. We hypothesized that the peripheral blood T-cell activation status may be a predictor of response, progression free survival (PFS) and overall survival (OS). Methods: Three immunotherapy regimes were combined with SBRT in sequential cohorts as ≥2nd line in CPI naïve patients with NSCLC stage IIIB/IV. One week after the 1st dose of CPI, patients were irradiated on the primary tumor (1x 20Gy on 9cc). The 1st cohort (n=3) received durvalumab, the 2nd and 3rd cohort (both n=6) a combination of durvalumab and tremelimumab, followed by durvalumab monotherapy. Exploratory endpoint was the correlation of response with T-cell function. T-cell function was assessed using flow cytometric analysis of peripheral blood T-cells and compared to simultaneously included healthy controls. In short, whole blood was activated ex vivo using Staphylococcal enterotoxin B (SEB) after which the T-cell activation status was assesses by expression of CD69 and cytokines (IL-2, IFN-γ, TNF-α). Patients were divided in above (responders, R) and below median PFS (non-responders, NR). We compared intracellular cytokine production in both CD4+ and CD8+ T-lymphocytes between both groups and with healthy controls (HC) using the Mann-Whitney U test. Findings: Fifteen patients were included as described above. Median PFS was 2 months, OS 10 months (immature). Baseline characteristics of both groups were comparable. T-cell function was assessed in 14 patients and HC at baseline. Data are shown as median (P-value) for R vs NR below. R had a significant higher percentage activated CD8+ T-cells upon SEB stimulation than NR: CD8+CD69+ 15.8 vs 3.5 (0.008) and IL-2+CD8+CD69+ 8.8 vs 2.9 (0.02). There was a trend in TNF-α+CD8+CD69+ 19.8 vs 8.0 (0.11) and IFN-ɣ+CD8+CD69+ 21.4 vs 5.5 (0.22). These differences were all significant for R compared to HC (p 0.66). Interpretation: With a mild antigen independent stimulus (SEB), the CD8+ T-cells of responders were significantly more activated at baseline compared to non-responders and healthy controls. This suggests an elevated pre-treatment T-cell activation status in patients that responded to the treatment and the possibility to use this as a potential biomarker to predict the response to CPI treatment. Disclosure: This study was sponsored by a research grant from AstraZeneca. Citation Format: Hanneke Kievit, M. Benthe Muntinghe-Wagenaar, Lucie B.M. Hijmering-Kappelle, Birgitta I. Hiddinga, J Fred Ubbels, Robin Wijsman, Bart-Jan Kroesen, Marcel J. van der Leij, A. Rutgers, Harry J. Groen, Huib A. Kerstjens, Anthonie J. van de Wekken, T Jeroen Hiltermann. Baseline T-cell function predicts response to SBRT and immunotherapy in NSCLC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 1984.

Clinical outcome following checkpoint therapy in renal cell carcinoma is associated with a burst of activated CD8 T cells in blood

Tumor-Infiltrating and Peripheral Blood T-cell Immunophenotypes Predict Early Relapse in Localized Clear Cell Renal Cell Carcinoma

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

Single-Cell Analysis Identifies Distinct Populations of Cytotoxic CD4+ T Cells Linked to the Therapeutic Efficacy of Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma

Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging

Abstract 3308: Predictive biomarkers of response to immune checkpoint inhibitors in metastatic renal cell carcinoma

Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer

Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies

Checkpoint Molecule PD-1-assisted CD8+ T Lymphocyte Count in Tumor Microenvironment Predicts Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.

Microenvironment of metastasis reveals key predictors of PD-1 blockade response in renal cell carcinoma

CD57-positive CD8 + T cells define the response to anti-programmed cell death protein-1 immunotherapy in patients with advanced non-small cell lung cancer

Favorable Immunotherapy Plus Tyrosine Kinase Inhibition Outcome of Renal Cell Carcinoma Patients with Low CDK5 Expression

Diversity of Dominant Peripheral T Cell Receptor Clone and Soluble Immune Checkpoint Proteins Associated With Clinical Outcomes Following Immune Checkpoint Inhibitor Treatment in Advanced Cancers

Baseline Blood CD8+ T Cell Activation Potency Discriminates Responders from Non-Responders to Immune Checkpoint Inhibition Combined with Stereotactic Radiotherapy in Non-Small-Cell Lung Cancer

Single cell phenotyping of PDL1 and HLA1 on circulating tumor cells (CTC) in clear cell renal cell carcinoma (ccRCC) on systemic treatment with immunotherapy (IO) and vascular endothelial growth factor receptor tyrosine kinase inhibitors (TKI).

Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma

A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy

Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition

Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma

The Prognostic Significance of CDK6 Expression in Renal Cell Carcinoma Treated by Immune Checkpoint Plus Tyrosine Kinase Inhibition.

Abstract 1984: Baseline T-cell function predicts response to SBRT and immunotherapy in NSCLC